Clinicians should be aware of the strengths and weaknesses of diabetes apps and be able to advise patients on their use, according to the European Association for the Study of Diabetes and the American Diabetes Association.
While we could not determine causality between insulin and mortality, we highlight a vulnerable population which needs additional resources in the discharge transition period,” the authors wrote.
Glycemic control as measured by HbA1c level remains strongly and independently associated with cardiovascular outcomes in high-risk patients with diabetes on statin therapy.
The frequency of diabetes visits varied across health systems, but within most of the studied organizations, patients with high HbA1c levels were not seen any more often than those with lower levels.
While the proportion of U.S. adults with diabetes who attained glycemic, blood pressure, and lipid control increased during the study period, there was a lack of progress related to dietary guidelines.
An analysis of patients with insulin-treated diabetes found that 38% of those with late-onset type 1 diabetes did not receive insulin at diagnosis, nearly half of whom reported a type 2 diabetes diagnosis.
probably indicates a more accelerated intimal hyperplasia, greater degree of vascular inflammation and/or endothelial dysfunction, and increased plaque vulnerability in insulin-treated diabetic patients, and highlights the need for
A recent scientific statement on diabetes and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes on outcomes in heart failure; reviews pharmacological therapy and lifestyle modification; highlights the value
Other independent predictors of long-term weight loss included greater weight loss in the first year and older age, according to this follow-up analysis of the Diabetes Prevention Program.
Incorporating intensive weight management with a low-carb diet into standard group medical visits for patients with diabetes “should be considered as an alternative, noninferior approach for glycemic management that has additional clinical